Year in Review

Share

Program Content

Activities

  • Inhibiteur BTK pour le traitement de la LLC ou du LCM récidivant/réfractaire
    Une perspective globale sur les données émergentes relatives à la thérapie par inhibiteurs BTK chez les patients atteints de LLC ou du LCM récidivant/réfractaire en 2022
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 13, 2023

    Expires: January 12, 2024

  • BTKi in R/R CLL and MCL
    A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

  • BTKi bei R/R CLL und MCL
    Eine globale Perspektive: Neue Daten zur BTK-Inhibitor-Therapie bei rezidivierter/refraktärer CLL und MCL in 2022
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 10, 2023

    Expires: January 09, 2024

  • BTKi em LLC e LCM R/R
    Uma perspectiva global sobre os dados emergentes da terapia com inibidor de BTK para LLC e LCM recidivantes/refratários em 2022
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 13, 2023

    Expires: January 12, 2024

  • Inhibidores de TQB para LLC y LCM R/R
    Perspectiva global sobre los datos de tratamientos emergentes con inhibidores de TQB para LLC y LCM en recidiva/refractarios en 2022
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 23, 2023

    Expires: January 22, 2024

Faculty

cover img faculity

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

cover img faculity

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Toby A Eyre, MBChB, MD

Hematology Consultant
Honorary Senior Lecturer at the University of Oxford
Oxford University Hospitals NHS Trust
Oxford, United Kingdom

cover img faculity

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

cover img faculity

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

cover img faculity

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

cover img faculity

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly